Therefore, our results suggest that urinary levels of TNF-α are higher in patients with AKI-ICI with pathology demonstrating AIN, and thus may serve as a useful biomarker to distinguish AKI-ICI from other clinical causes of AKI while on ICI therapy. The gene discussed is TNF; the disease is acute kidney injury.